Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Revenue Projected To Hit $82.6 Billion By 2030 With 15.8% CAGR

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Expected To Reach Based On Its 2026 Value?

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market size has expanded significantly in recent years. Projections indicate it will advance from $39.69 billion in 2025 to $45.88 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.6%. This historical growth can be attributed to various factors, including covid 19 vaccine breakthroughs, prior viral vector research, global pandemic preparedness programs, advances in genomic sequencing, and early nucleic acid vaccine trials.

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market is anticipated to experience significant expansion in the upcoming years. It is projected to achieve a size of $82.61 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.8%. This growth during the forecast period can be attributed to factors such as the development of personalized cancer vaccines, the broadening of infectious disease pipelines, more rapid platform-based approvals, increased funding in biotechnology, and the wider application of therapeutic vaccines. Prominent trends expected in the forecast period include self-amplifying mrna platforms, optimized lipid nanoparticle delivery, modular vaccine platform designs, swift adaptation to pathogen targets, and innovative next-generation adjuvant systems.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33215&type=smp

What Key Drivers Are Fueling The Growth Of The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

Future expansion of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market is anticipated due to the rising need for personalized medicine. Personalized medicine involves a healthcare strategy that customizes disease prevention and treatment plans according to an individual’s unique genetic makeup, molecular traits, and particular health circumstances. The escalating requirement for personalized medicine stems from the increasing occurrence of intricate and long-term illnesses, which necessitate precise and individualized therapeutic approaches to enhance both the effectiveness and safety of treatment. Messenger ribonucleic acid (mRNA) and next-generation vaccine platforms facilitate personalized medicine by allowing for quick, adaptable, and highly precise designs for vaccines and therapies, which can be adapted to specific genetic and disease profiles of individuals, thereby aiding in the provision of precision healthcare. As an illustration, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported in February 2024 that the FDA cleared 16 novel personalized treatments for patients with rare diseases in 2023, an increase from six in 2022. Consequently, the expanding need for personalized medicine is fueling the expansion of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market.

What Are The Different Segment Types In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Segment Breakdown?

The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market covered in this report is segmented –

1) By Vaccine Type: Messenger Ribonucleic Acid Vaccines; Deoxyribonucleic Acid (DNA) Vaccines; Viral Vector Vaccines; Protein Subunit Vaccines; Peptide Vaccines; Other Vaccine Types

2) By Technology or Platform: Lipid Nanoparticle (LNP) Delivery; Self-Amplifying Messenger Ribonucleic Acid; Circular Messenger Ribonucleic Acid; Replicon or Non-replicating Platforms; Viral Vector Technologies

3) By Disease Indication: Infectious Diseases; Oncology; Rare Diseases; Other Disease Indications

4) By End User: Pharmaceutical and Biotechnology Companies; Contract Research Organizations (CROs); Academic and Research Institutes; Hospitals and Clinics

Subsegments:

1) By Messenger Ribonucleic Acid Vaccines: Conventional Messenger Ribonucleic Acid Vaccines; Self Amplifying Messenger Ribonucleic Acid Vaccines; Modified Messenger Ribonucleic Acid Vaccines; Circular Messenger Ribonucleic Acid Vaccines

2) By Deoxyribonucleic Acid Vaccines: Plasmid Deoxyribonucleic Acid Vaccines; Viral Assisted Deoxyribonucleic Acid Vaccines; Synthetic Deoxyribonucleic Acid Vaccines; Gene Based Deoxyribonucleic Acid Vaccines

3) By Viral Vector Vaccines: Adenovirus Based Viral Vector Vaccines; Lentivirus Based Viral Vector Vaccines; Poxvirus Based Viral Vector Vaccines; Measles Virus Based Viral Vector Vaccines

4) By Protein Subunit Vaccines: Recombinant Protein Vaccines; Virus Like Particle Vaccines; Toxoid Based Protein Vaccines; Polysaccharide Conjugate Vaccines

5) By Peptide Vaccines: Synthetic Peptide Vaccines; Personalized Peptide Vaccines; Multi Epitope Peptide Vaccines; Long Peptide Vaccines

6) By Other Vaccine Types: Protein Subunit Vaccines, Virus-Like Particle Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vector Vaccines

What Trends Are Influencing The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

Leading companies operating in the mRNA and next-generation vaccine platforms market are concentrating their efforts on the creation of advanced mRNA-based COVID-19 vaccines. This focus aims to boost immune durability, expand variant coverage, and elevate overall vaccine efficacy. These innovative mRNA-based COVID-19 vaccines harness enhanced mRNA engineering and sophisticated delivery technologies, providing more extensive and lasting protection against both current and emerging SARS-CoV-2 variants. Furthermore, they offer improved safety, greater stability, and enhanced storage convenience, alongside the capability for swift adaptation to viral evolution. As an illustration, in June 2025, Moderna Inc., a US-based biotechnology company, launched mNEXSPIKE, its next-generation COVID-19 vaccine. This vaccine is engineered to enhance protection against both circulating and newly emerging SARS-CoV-2 variants. mNEXSPIKE features an updated spike protein antigen, which more closely aligns with recent variants, and is intended to deliver superior immune durability and effectiveness, thereby bolstering ongoing COVID-19 prevention initiatives and future booster strategies.

Who Are The Well-Known Companies In The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market?

Major companies operating in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Moderna Inc., BioNTech SE, Novavax Inc., Walvax Biotechnology Co Ltd, Arcturus Therapeutics Inc, Gennova Biopharmaceuticals Ltd, Vaxxas Pty Ltd, Vaxart Inc, Ethris GmbH, The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited, eTheRNA Immunotherapies NV, Stemirna Therapeutics Co Ltd, Primrose Bio Inc, Acuitas Therapeutics Inc, and Incepta Vaccine Ltd.

Get The Full Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Report:

https://www.thebusinessresearchcompany.com/report/messenger-ribonucleic-acid-mrna-and-next-generation-vaccine-platforms-market-report

Which Region Dominates The Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market By Market Share?

North America was the largest region in the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=33215&type=smp

Browse Through More Reports Similar to the Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market 2026, By The Business Research Company

Mrna Cancer Vaccines And Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-cancer-vaccines-and-therapeutics-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info